Spain. Effective June 2005, the Spanish Agency for Medicines and Medical Devices has suspended the marketing authorization for veralipride (Agreal) in Spain. This action is based on the conclusions of the Spanish Medicines Safety Committee that reviewed reports of psychiatric and neurological disorders and of withdrawal symptoms associated with veralipride use. The Agency has released a press statement on its website and has communicated this information to all health professionals in the country.

Reference:

Communicaçión. Agencia Espanola de medicamentos (Agemed), 20 May 2005 (http://www.agemed.es).